查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1542954

全球低溫治療市場 - 2024-2031

Global Therapeutic Hypothermia Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

2023年，全球低溫治療市場達到2.88億美元，預計2031年將達到4.5811億美元，2024-2031年預測期間複合年成長率為6.1%。

治療性低溫或溫度管理是一種積極的治療方法，試圖在特定的時間內達到並維持人的特定體溫，以改善大腦血流停止一段時間後恢復期間的健康結果。這樣做是為了降低血流不足導致組織損傷的風險。血流不良的時期可能是由於心臟驟停或血栓堵塞動脈（如中風）造成的。

低溫治療的有益效果也已被發現，並且透過與其他神經保護治療相結合以及探索低溫神經保護機制，在進一步提高低溫治療的益處方面取得了進展。

市場動態：

司機

神經系統和心血管疾病的盛行率不斷增加

全球低溫治療市場的需求是由多種因素所驅動的。神經系統和心血管疾病盛行率的上升推動了市場的成長。例如，根據世界心臟聯合會 2023 年 5 月 20 日發表的一篇文章，心血管疾病導致的死亡人數已從 1990 年的 1,210 萬人增加到近年來的 2,050 萬人。近年來，空氣污染、菸草使用以及心血管疾病導致的死亡人數增加，導致高血壓病例增加。

根據世界衛生組織網站2024年3月發布的一篇文章，神經系統疾病近年來增加了18%，超過三分之一的人患有神經系統疾病。據估計，全球總人口中有超過 30 億人患有神經系統疾病。與女性相比，神經系統疾病會導致男性有更多的殘疾和健康損失，但偏頭痛或失智症等某些疾病對女性的影響尤其嚴重。

限制

與低溫治療相關的程序的複雜性和嚴格的監管要求等因素預計將阻礙市場的發展。

細分市場分析

全球低溫治療市場根據產品類型、應用、最終用戶和地區進行細分。

神經科細分市場約佔全球低溫治療市佔率的43.4%

預計神經病學領域將在預測期內佔據最大的市場佔有率。在該細分市場中，神經系統疾病盛行率的增加以及該細分市場中治療性低溫療法使用的增加將推動該市場的發展。

根據 nih.gov 報告，低溫治療對心臟驟停患者和新生兒 HIE 患者均具有神經保護作用，並有望同樣降低缺血性中風後的發病率和死亡率。事實上，一些臨床前研究表明，在最近的一項薈萃分析中，在急性缺血性中風期間或短暫延遲後開始的輕度治療性低溫可減少梗塞面積並減輕功能障礙。除了這些研究之外，另一項研究也顯示了可行性和耐受性，並制定了預防或減少通常清醒的中風患者顫抖的方案。

例如，在最近的一項多中心研究中，血管內冷卻裝置與重組組織纖溶酶原活化劑（rt-PA）聯合用於急性中風患者。在這裡，患者可以在症狀出現後 0-6 小時內接受治療，然後血管內冷卻至 33°C，持續 24 小時。雖然研究的目的不是評估低溫治療的相對功效，但這種治療方案似乎具有良好的耐受性，儘管降溫患者中肺炎的發生率增加。一些缺血性中風的臨床試驗顯示了低溫治療的良好效果。

市場地理分析

北美約佔全球低溫治療市場佔有率的 47.2%

預計北美地區將在預測期內佔據最大的市場佔有率。神經系統和心血管疾病的發生率不斷上升，人們對低溫治療的好處的認知不斷提高，以及該地區主要參與者的存在，都有助於推動市場發展。

例如，根據泛美衛生組織 (PAHO) 2024 年 3 月發布的一篇文章，美國已有 5,33,172 人死於各種神經系統疾病和病症。在這 5,33,172 例死亡中，男性 2,13,129 例，女性 3,20,043 例。在美國總人口中，每 10 萬人中有 32.9 人死亡。在男性人口中，每10萬人中有33.1人死亡，在女性人口中，每10萬人中有32.2人死亡。

此外，根據 cdc.gov 2024 年 5 月發布的一篇文章，心血管疾病是美國人口死亡的主要原因。每 33 秒就有 1 人因心血管疾病死亡。每 5 人死亡就有 1 人死於心血管疾病。神經系統和心血管疾病盛行率的增加是主要促進因素，北美地區佔據了最大的市場佔有率。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 神經系統和心血管疾病的盛行率不斷增加
      • 技術進步
      • 提高對低溫治療益處的認知
    • 限制
      • 手術中涉及的併發症
      • 嚴格的監管要求
  • 機會
  • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 未滿足的需求
  • PESTEL分析
  • 專利分析
  • SWOT分析

第 6 章：依產品類型

  • 表面冷卻包
  • 表面式熱交換裝置
  • 表面冷卻頭盔
  • 導管技術
  • 冷輸液
  • 其他

第 7 章：按申請

  • 神經病學
  • 心臟病學
  • 新生兒護理

第 8 章：最終用戶

  • 醫院
  • 專科診所
  • 救護車和緊急醫療服務
  • 學術及研究機構
  • 其他

第 9 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 和年成長分析（%），按配銷通路
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
      • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 10 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 11 章：公司簡介

  • Asahi Kasei Corporation
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Becton Dickinson and Company
  • Shenzhen Comen Medical Instruments Co.
  • Terumo Cardiovascular Systems Co.
  • Phoenix Medical Systems
  • Gentherm Medicals
  • International Biomedical Ltd.
  • Global Health Care SG
  • Stryker Corporation
  • Aspen Systems (*LIST NOT EXHAUSTIVE)

第 12 章：附錄

簡介目錄
Product Code: MD8605

Report Overview

The Global Therapeutic Hypothermia Market reached US$ 288 million in 2023 and is expected to reach US$ 458.11 million by 2031, growing at a CAGR of 6.1% during the forecast period 2024-2031.

Therapeutic hypothermia or temperature management is an active treatment that tries to achieve and maintain a specific body temperature in a person for a specific duration of time to improve health outcomes during recovery after a period of stopped blood flow to the brain. This is done in an attempt to reduce the risk of tissue injury following a lack of blood flow. Periods of poor blood flow may be due to cardiac arrest or the blockage of an artery by a clot as in the case of a stroke.

Beneficial effects of therapeutic hypothermia have also been discovered, and progress has been made toward improving the benefits of therapeutic hypothermia further through combination with other neuroprotective treatments and by probing the mechanism of hypothermia neuroprotection.

Market Dynamics: Drivers

Increasing prevalence of neurological and cardiovascular diseases

The demand for the global therapeutic hypothermia market is driven by multiple factors. The rising prevalence of neurological and cardiovascular diseases propels the market growth. For instance, according to the World Heart Federation.org, an article published on 20 May 2023, deaths due the cardiovascular diseases have increased from 12.1 million in 1990 to 20.5 million in recent times. The increase in air pollution, tobacco use, and increase in high blood pressure cases increased from deaths due to cardiovascular diseases in recent times.

According to an article posted on the World Health Organization website in March 2024, neurological diseases have increased by 18% in recent times, and over 1 in every 3 people are being affected by neurological disorders. It is estimated that more than 3 billion people are living with neurological diseases among the overall global population. Neurological conditions cause more disability and health loss in men compared to women, but there are some conditions like migraine or dementia where women are disproportionately affected.

Restraints

Factors such as the complexity involved in the procedures related to therapeutic hypothermia and stringent regulatory requirements are expected to hamper the market.

Market Segment Analysis

The global therapeutic hypothermia market is segmented based on product type, application, end-user, and region.

The segment neurology accounted for approximately 43.4% of the global therapeutic hypothermia market share

The neurology segment is expected to hold the largest market share over the forecast period. In this segment, the increase in the prevalence of neurological diseases and the increase in the usage of therapeutic hypothermia in this segment would drive this market.

According to nih.gov, therapeutic hypothermia was shown to be neuroprotective in both cardiac arrest patients and neonatal HIE patients, there is hope that it will similarly reduce morbidity and mortality following ischemic stroke. Indeed, a few preclinical studies showed that mild therapeutic hypothermia initiated during acute ischemic stroke or after a short delay reduced infarct size and mitigated functional impairment in a recent meta-analysis. In addition to these studies, another study showed feasibility and tolerability and established regimens to prevent or reduce shivering in the typically awake stroke patient.

For instance, in a recent multicenter study, an endovascular cooling device was used in combination with the administration of recombinant tissue plasminogen activator (rt-PA) in acute stroke patients. Here, patients could be treated within 0-6 h of symptom onset followed by endovascular cooling to 33oC for 24 h. While the study was not designed to evaluate the relative efficacy of therapeutic hypothermia, this regimen appeared well tolerated, although there was an increased incidence of pneumonia amongst cooled patients. A few clinical trials in ischemic stroke showed promising effects of therapeutic hypothermia.

Market Geographical Analysis

North America accounted for approximately 47.2% of the global therapeutic hypothermia market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of neurological and cardiovascular diseases, growing awareness among people about the benefits that are associated with therapeutic hypothermia, and the presence of major players in this region, help to propel the market.

For instance, according to an article posted by the Pan American Health Organization (PAHO) in March 2024, there have been 5,33,172 deaths due to various neurological disorders and conditions in the US. Among these 5,33,172 deaths, 2,13,129 were male and the remaining 3,20,043 were female. In the entire population of the US, there are 32.9 deaths per 100,000 population. In the men population, there are 33.1 deaths per 100,000 population, and in the female population, there are 32.2 deaths per 100,000 population.

Moreover, according to an article posted in May 2024 by cdc.gov, cardiovascular diseases are the leading cause of death among the population in the US. For every 33 seconds, one person is being dead due to cardiovascular disease. 1 in every 5 deaths is due to the cardiovascular disease. The increase in prevalence of neurological and cardiovascular diseases being the main driving factor is seen in the North American region which accounts for the largest market share.

Market Segmentation

By Product Type

  • Surface cooling packs
  • Surface heat exchange device
  • Surface cooling helmet
  • Catheter technology
  • Cold fluids infusion
  • Others

By Application

  • Neurology
  • Cardiology
  • Neo-natal care

By End-User

  • Hospitals
  • Specialty Clinics
  • Ambulance and Emergency Medical Service
  • Academic and Research Institutes
  • Others

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
  • Middle East and Africa

Market Competitive Landscape

The major global players in the global therapeutic hypothermia market include Asahi Kasei Corporation, Becton Dickinson and Company, Shenzhen Comen Medical Instruments Co., Terumo Cardiovascular Systems Corporation, Phoenix Medical Systems, Gentherm Medicals, International Biomedical Ltd., Global Healthcare SG, Stryker Corporation, Aspen Systems among others.

Key Developments

  • In 2023, a medical device manufacturing company braincool which manufactures and offers therapeutic hypothermia systems signed an agreement with the Asahi Kasei Corporation, a Japan-based company for cooling systems and cooling pads for European and US markets.
  • In January 2024, SourceMark Medicals announced an expanded partnership with Gentherm Medicals. SourceMark is the master supplier of certain Gentherm patient warming product lines in the United States, including Astopad(R), a resistive warming system designed to prevent and treat hypothermia, Norm-O-Temp(R), a whole-body hyperthermia system, Gelli-Roll(R), a reusable warming and cooling gel pad, the WarmAir(R) convective patient warming system, and FilteredFlo(R) patient warming air blankets.
  • In March 2023, a company called NICE came into partnership with Aspen Group. This partnership leverages NICE's advanced cold compression technology with Aspen's effective bracing solutions to deliver pain management and post-operative care to patients recovering from surgery or injury. NICE therapy pads seamlessly attach to the market-leading Vista Cervical Collar and the Horizon 637, allowing patients to receive cold therapy pneumatic compression in an all-in-one, easy-to-use device. This reduces symptoms of swelling, assists with lymphatic drainage, and improves recovery outcomes.

Why Purchase the Report?

  • To visualize the global therapeutic hypothermia market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of global therapeutic hypothermia market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in Excel consisting of key products of all the major players.

The global therapeutic hypothermia market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Neurological and Cardiovascular Diseases
      • 4.1.1.2. Technological Advancements
      • 4.1.1.3. Increase in Awareness regarding the benefits of therapeutic hypothermi
    • 4.1.2. Restraints
      • 4.1.2.1. Complications involved in procedures
      • 4.1.2.2. Stringent Regulatory Requirements
  • 4.2. Opportunity
  • 4.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. PESTEL Analysis
  • 5.7. Patent Analysis
  • 5.8. SWOT Analysis

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Surface Cooling Packs*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Surface Heat Exchange Device
  • 6.4. Surface Cooling Helmet
  • 6.5. Catheter Technology
  • 6.6. Cold Fluids Infusion
  • 6.7. Others

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Neurology*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Cardiology
  • 7.4. Neo-natal Care

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Specialty Clinics
  • 8.4. Ambulance and Emergency Medical Services
  • 8.5. Academic and Research Institutes
  • 8.6. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. UK
      • 9.3.7.3. France
      • 9.3.7.4. Italy
      • 9.3.7.5. Spain
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Asahi Kasei Corporation *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Becton Dickinson and Company
  • 11.3. Shenzhen Comen Medical Instruments Co.
  • 11.4. Terumo Cardiovascular Systems Co.
  • 11.5. Phoenix Medical Systems
  • 11.6. Gentherm Medicals
  • 11.7. International Biomedical Ltd.
  • 11.8. Global Health Care SG
  • 11.9. Stryker Corporation
  • 11.10. Aspen Systems (*LIST NOT EXHAUSTIVE)

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us